Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADORE: Mepolizumab in COPD Patients
NCT07749001Phase 4Not yet recruiting
- Sponsor
- Western University
- Start
- Oct 2026
- Primary completion
- Feb 2028
01
Overview
Phase 4, open-label, single-arm trial of mepolizumab in chronic obstructive pulmonary disease (COPD), sponsored by Western University. Primary endpoints: MRI ventilation defect percent at 48 weeks and CT airway mucus-count at 48 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07749001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749001.